Cargando…

Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles

Oxyresveratrol, a stilbene extracted from the plant Artocarpus lakoocha Roxb., has been reported to provide a considerable anti-inflammatory activity. Since the mechanisms of this therapeutic action have been poorly clarified, we investigated whether oxyresveratrol affects the release of the pro-inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaglio, Salvatore Calogero, Donini, Marta, Denbaes, Piyachat Evelyn, Dusi, Stefano, Perduca, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067564/
https://www.ncbi.nlm.nih.gov/pubmed/33916909
http://dx.doi.org/10.3390/molecules26082106
_version_ 1783682833263362048
author Gaglio, Salvatore Calogero
Donini, Marta
Denbaes, Piyachat Evelyn
Dusi, Stefano
Perduca, Massimiliano
author_facet Gaglio, Salvatore Calogero
Donini, Marta
Denbaes, Piyachat Evelyn
Dusi, Stefano
Perduca, Massimiliano
author_sort Gaglio, Salvatore Calogero
collection PubMed
description Oxyresveratrol, a stilbene extracted from the plant Artocarpus lakoocha Roxb., has been reported to provide a considerable anti-inflammatory activity. Since the mechanisms of this therapeutic action have been poorly clarified, we investigated whether oxyresveratrol affects the release of the pro-inflammatory cytokines IL-12, IL-6, and TNF-α by human dendritic cells (DCs). We found that oxyresveratrol did not elicit per se the release of these cytokines, but inhibited their secretion induced upon DC stimulation with R848 (Resiquimod), a well-known immune cell activator engaging receptors recognizing RNA viruses. We then investigated whether the inclusion of oxyresveratrol into nanoparticles promoting its ingestion by DCs could favor its effects on cytokine release. For this purpose we synthesized and characterized poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and we assessed their effects on DCs. We found that bare PLGA nanoparticles did not affect cytokine secretion by resting DCs, but increased IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs, an event known as “priming effect”. We then loaded PLGA nanoparticles with oxyresveratrol and we observed that oxyresveratrol-bearing particles did not stimulate the cytokine release by resting DCs and inhibited the PLGA-dependent enhancement of IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs. The results herein reported indicate that oxyresveratrol suppresses the cytokine production by activated DCs, thus representing a good anti-inflammatory and immune-suppressive agent. Moreover, its inclusion into PLGA nanoparticles mitigates the pro-inflammatory effects due to cooperation between nanoparticles and R848 in cytokine release. Therefore, oxyresveratrol can be able to contrast the synergistic effects of nanoparticles with microorganisms that could be present in the patient tissues, therefore overcoming a condition unfavorable to the use of some nanoparticles in biological systems.
format Online
Article
Text
id pubmed-8067564
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80675642021-04-25 Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles Gaglio, Salvatore Calogero Donini, Marta Denbaes, Piyachat Evelyn Dusi, Stefano Perduca, Massimiliano Molecules Article Oxyresveratrol, a stilbene extracted from the plant Artocarpus lakoocha Roxb., has been reported to provide a considerable anti-inflammatory activity. Since the mechanisms of this therapeutic action have been poorly clarified, we investigated whether oxyresveratrol affects the release of the pro-inflammatory cytokines IL-12, IL-6, and TNF-α by human dendritic cells (DCs). We found that oxyresveratrol did not elicit per se the release of these cytokines, but inhibited their secretion induced upon DC stimulation with R848 (Resiquimod), a well-known immune cell activator engaging receptors recognizing RNA viruses. We then investigated whether the inclusion of oxyresveratrol into nanoparticles promoting its ingestion by DCs could favor its effects on cytokine release. For this purpose we synthesized and characterized poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and we assessed their effects on DCs. We found that bare PLGA nanoparticles did not affect cytokine secretion by resting DCs, but increased IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs, an event known as “priming effect”. We then loaded PLGA nanoparticles with oxyresveratrol and we observed that oxyresveratrol-bearing particles did not stimulate the cytokine release by resting DCs and inhibited the PLGA-dependent enhancement of IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs. The results herein reported indicate that oxyresveratrol suppresses the cytokine production by activated DCs, thus representing a good anti-inflammatory and immune-suppressive agent. Moreover, its inclusion into PLGA nanoparticles mitigates the pro-inflammatory effects due to cooperation between nanoparticles and R848 in cytokine release. Therefore, oxyresveratrol can be able to contrast the synergistic effects of nanoparticles with microorganisms that could be present in the patient tissues, therefore overcoming a condition unfavorable to the use of some nanoparticles in biological systems. MDPI 2021-04-07 /pmc/articles/PMC8067564/ /pubmed/33916909 http://dx.doi.org/10.3390/molecules26082106 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gaglio, Salvatore Calogero
Donini, Marta
Denbaes, Piyachat Evelyn
Dusi, Stefano
Perduca, Massimiliano
Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles
title Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles
title_full Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles
title_fullStr Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles
title_full_unstemmed Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles
title_short Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles
title_sort oxyresveratrol inhibits r848-induced pro-inflammatory mediators release by human dendritic cells even when embedded in plga nanoparticles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067564/
https://www.ncbi.nlm.nih.gov/pubmed/33916909
http://dx.doi.org/10.3390/molecules26082106
work_keys_str_mv AT gagliosalvatorecalogero oxyresveratrolinhibitsr848inducedproinflammatorymediatorsreleasebyhumandendriticcellsevenwhenembeddedinplgananoparticles
AT doninimarta oxyresveratrolinhibitsr848inducedproinflammatorymediatorsreleasebyhumandendriticcellsevenwhenembeddedinplgananoparticles
AT denbaespiyachatevelyn oxyresveratrolinhibitsr848inducedproinflammatorymediatorsreleasebyhumandendriticcellsevenwhenembeddedinplgananoparticles
AT dusistefano oxyresveratrolinhibitsr848inducedproinflammatorymediatorsreleasebyhumandendriticcellsevenwhenembeddedinplgananoparticles
AT perducamassimiliano oxyresveratrolinhibitsr848inducedproinflammatorymediatorsreleasebyhumandendriticcellsevenwhenembeddedinplgananoparticles